Immuneering
IMRX
37 hedge funds and large institutions have $200M invested in Immuneering in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 20 increasing their positions, 4 reducing their positions, and 5 closing their positions.
400% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 4
115% more capital inflows, than outflows
Capital inflows: $17.7M | Capital outflows: $8.26M
1.53% more ownership
Funds ownership: 46.67% → 48.19% (+1.5%)
3% less funds holding
Funds holding: 38 → 37 (-1)
20% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$7.64M |
| 2 |
BlackRock
New York
|
+$4.67M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.81M |
| 4 |
Cormorant Asset Management
Boston,
Massachusetts
|
+$1.22M |
| 5 |
State Street
Boston,
Massachusetts
|
+$456K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$4.1M |
| 2 |
Millennium Management
New York
|
-$1.46M |
| 3 |
CCM
CAAS Capital Management
New York
|
-$1.06M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$723K |
| 5 |
Ghisallo Capital Management
Boston,
Massachusetts
|
-$398K |
IMRX Hedge Fund Activity: Q4 2021 in Review
37 of the 6,523 institutional investors tracked by Wall St. Rank reported a position in Immuneering (IMRX) for Q4 2021, worth a combined $200M — down 37% from $316M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMRX and 4 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 20 added.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $7.64M. The largest seller was Fidelity Investments, cutting an estimated $4.1M.
- 37 institutional investors held Immuneering (IMRX) as of Q4 2021, down from 38 in Q3 2021.
- Funds reported $200M of Immuneering stock for Q4 2021, down 37% quarter-over-quarter.
- 4 funds opened new Immuneering positions in Q4 2021 and 5 closed out, a net change of -1 holder.
- The largest Immuneering buyer in Q4 2021 was Adage Capital Partners, an estimated $7.64M added.
- The largest Immuneering seller in Q4 2021 was Fidelity Investments, an estimated $4.1M sold.
Based on aggregated 13F filings for Q4 2021.